Discontinuation report ATRIPLA
| Report ID | 144260 |
| Drug Identification Number | 02300699 |
| Brand name | ATRIPLA |
| Common or Proper name | efavirenz/emtricitabine/tenofovir disoproxil fumarate |
| Company Name | GILEAD SCIENCES, LLC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ |
| Strength(s) | 300MG 200MG 600MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | Each bottle contains 30 tablets |
| ATC code | J05AR |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2021-12-31 |
| Actual discontinuation date | 2021-12-31 |
| Remaining supply date | 2021-12-31 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Sufficient supply to meet patient need to discontinuation date. |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 333 LAKESIDE DRIVE FOSTER CITY, CALIFORNIA UNITED STATES 94404 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2021-08-17 | English | Compare |
| v2 | 2021-08-17 | French | Compare |
| v3 | 2021-08-17 | French | Compare |
| v4 | 2022-01-01 | English | Compare |
Showing 1 to 4 of 4